Get the Stockscreener App
0.06
4.15%
-0.0026
After Hours:
.06
Eyenovia Inc stock is traded at $0.06, with a volume of 14.17M.
It is down -4.15% in the last 24 hours and down -29.66% over the past month.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
See More
Previous Close:
$0.0626
Open:
$0.0601
24h Volume:
14.17M
Relative Volume:
0.65
Market Cap:
$6.69M
Revenue:
-
Net Income/Loss:
$-37.28M
P/E Ratio:
-0.0769
EPS:
-0.78
Net Cash Flow:
$-32.24M
1W Performance:
-30.23%
1M Performance:
-29.66%
6M Performance:
-94.59%
1Y Performance:
-96.10%
1-Day Range:
$0.0551
$0.0625
1-Week Range:
$0.0551
$0.0857
52-Week Range:
$0.0551
$2.57
Eyenovia Inc Stock (EYEN) Company Profile
Name
Eyenovia Inc
Sector
Industry
Phone
813-766-9539
Address
295 MADISON AVENUE,, NEW YORK, NY
Compare EYEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYEN
Eyenovia Inc
|
0.06 | 6.69M | 0 | -37.28M | -32.24M | -0.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eyenovia Inc Stock (EYEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-01-21 | Initiated | Northland Capital | Outperform |
| Feb-03-20 | Downgrade | Oppenheimer | Outperform → Perform |
Eyenovia Inc Stock (EYEN) Latest News
Financial Survey: Mirum Pharmaceuticals (NASDAQ:MIRM) & Eyenovia (NASDAQ:EYEN) - Defense World
Eyenovia secures $1 million from warrant repricing and exercise - MSN
Eyenovia secures $1 million from warrant repricing and exercise By Investing.com - Investing.com Canada
SEC Form 424B3 filed by Eyenovia Inc. - Quantisnow
Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote 'FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders - The Manila Times
Eyenovia Announces Leading Proxy Advisory Firms, ISS and - GlobeNewswire
Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders - GlobeNewswire Inc.
Ladenburg Thalmann Downgrades Eyenovia (EYEN) - MSN
Geode Capital Management LLC Increases Stock Position in Eyenovia, Inc. (NASDAQ:EYEN) - Defense World
Deal Dispatch: TD Bank To Sell Charles Schwab Stake? Eyenovia, Smart Share Hit Auction Block - Benzinga
Mydriasis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight - The Globe and Mail
Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc - The Globe and Mail
Eyenovia Eyes Cost-Cutting Measures Amid Disappointing Study Results - MPO-mag
Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA - openPR
Eyenovia explores strategic alternatives, advances Optejet device By Investing.com - Investing.com Nigeria
Eyenovia Hires Financial Adviser Amid Business Review - MarketWatch
Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives - GlobeNewswire
Eyenovia explores strategic alternatives, advances Optejet device - Investing.com
Eyenovia Explores Strategic Alternatives, Accelerates Optejet Device Development Plans - StockTitan
Eyenovia (NASDAQ:EYEN) Enters into Amended and Restated Sales Agreement with Chardan Capital Markets, LLC - Defense World
Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews
SEC Form 424B5 filed by Eyenovia Inc. - Quantisnow
Eyenovia faces Nasdaq delisting over low stock price By Investing.com - Investing.com Nigeria
Eyenovia faces Nasdaq delisting over low stock price - Investing.com
Eyenovia (NASDAQ:EYEN) Announces Completion of Registered Direct Offering - Defense World
Eyenovia’s $1.9M Offering to Boost Optejet Development - TipRanks
Form 424B5 EYENOVIA, INC. - StreetInsider.com
Eyenovia announces pricing of $1.9M registered direct offering - MSN
Eyenovia secures $1.9 million in direct offering By Investing.com - Investing.com Canada
Eyenovia secures $1.9 million in direct offering - Investing.com
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering - GlobeNewswire
Eyenovia Announces $1.9M Direct Offering to Fund Optejet Development, Strategic Growth - StockTitan
These Numbers Show Just How Powerful Eyenovia Inc (NASDAQ: EYEN) Stock Is - Stocks Register
Eyenovia, Inc. (NASDAQ:EYEN) Short Interest Update - Defense World
Eyenovia’s Direct Offering to Support Strategic Initiatives - TipRanks
Eyenovia secures $1.3 million in direct offering By Investing.com - Investing.com South Africa
Eyenovia defers loan payments, issues equity to lenders - Investing.com
Eyenovia defers loan payments, issues equity to lenders By Investing.com - Investing.com Canada
Eyenovia Slumps On Pricing Of Registered Direct Offering - Nasdaq
Eyenovia Restructures Finances and Leadership Team - TipRanks
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering - The Manila Times
Eyenovia secures $1.3 million in direct offering - Investing.com
Eyenovia Raises $1.3M in Direct Offering at $0.1076 Per Share with Warrants | EYEN Stock News - StockTitan
Eyenovia Inc Stock (EYEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):